SINGAPORE September 2023 : CellResearch Corporation Appoints Troels Jordansen as CEO of CellResearch Therapeutics (CRT)…
adminFebruary 8, 2024
CellResearch Therapeutics (CRT) is spin-out of CellResearch Corp; the company pioneering umbilical cord lining stem cells for multiple indications, with a strong R&D history. We have developments in diverse conditions such as diabetic foot ulcer, androgenic alopecia and beyond utilizing our powerful platform technology.
Latest News
SINGAPORE October 19, 2022: Dr Andrew Boulton joins CellResearch Corporation’s Therapeutics Scientific Advisory Board to…
adminFebruary 8, 2024
SINGAPORE 16 September 2022: CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®…
adminFebruary 8, 2024
SINGAPORE 25th August 2022:Dr Paul Kemp, lead inventor of Apligraf® the first FDA-approved multi-cell therapy,…
adminFebruary 8, 2024
SINGAPORE July 19, 2022: CellResearch Corporation (“CRC”), a Singapore biotech company, specialising in stem cell…
adminFebruary 8, 2024
SINGAPORE March 1st, 2022: CellResearch Corporation (CRC) has named former Mundipharma and Eirgen executive Olivia…
adminFebruary 8, 2024
Sign Up To Our Newsletter
Address
137 Market Street, L8 Grace Global Raffles Building. Singapore 048943.
Connect
Troels Jordansen, CEO. +31 6 1834 5326, Troels@CRT.bio
Olivia Sutton, CDO. +44 7946 227 314, Olivia@CRT.bio
© 2026 CellResearch Therapeutics